Newspaper Publication for un-audited Financials Results of the Company for the quarter ended on 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has published its unaudited standalone and consolidated results for the quarter and half year ended 30 September 2025, which were approved by the Board on 31 October 2025. On a standalone basis, total operating income rose to ₹976.21 lakhs (from ₹786.98 lakhs a year ago), and net profit after tax jumped to ₹81.76 lakhs (from ₹20.81 lakhs). On a consolidated basis, total income climbed to ₹1,193.28 lakhs (from ₹828.58 lakhs) and net profit after tax surged to ₹171.17 lakhs (from ₹28.15 lakhs). Standalone EPS stood at ₹0.60 for the quarter (vs ₹0.06 implied) and consolidated EPS at ₹0.78 (vs ₹0.22). The consolidated results include wholly owned subsidiary Eiko Scientific Solutions LLP, subsidiary Eikovivify Logistics Pvt Ltd, and associate Reflux Pharmaceuticals Pvt Ltd. The statutory auditor's limited review report had no qualifications or modifications.
Strong year-on-year growth in both revenue and profit on a consolidated basis is a positive signal for shareholders, though the small absolute size of the company means the results are unlikely to move the stock sharply on their own.